In mid-May, Moderna Therapeutics’ Covid-19 vaccine candidate, mRNA-1273, received Fast Track designation from the Food and Drug Administration (FDA). The FDA also approved Moderna to begin a Phase II clinical trial study a few days before the approval.

Fast Track designation, as well as the initiation of the Phase II trial, could mean mRNA-1273 is the first vaccine to be approved and launched for the Covid-19 pandemic. Read more here.